{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:22:44Z","timestamp":1793467364044,"version":"4.5.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The emergence of chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for diffuse large B-cell lymphoma (DLBCL); however, real-world experience reporting outcomes among older patients treated with CAR T-cell therapy is limited. We leveraged the 100% Medicare fee-for-service claims database and analyzed outcomes and cost associated with CAR T-cell therapy in 551 older patients (aged \u226565 years) with DLBCL who received CAR T-cell therapy between 2018 and 2020. CAR T-cell therapy was used in third line and beyond in 19% of patients aged 65 to 69 years and 22% among those aged 70 to 74 years, compared with 13% of patients aged \u226575 years. Most patients received CAR T-cell therapy in an inpatient setting (83%), with an average length of stay of 21 days. The median event-free survival (EFS) following CAR T-cell therapy was 7.2 months. Patients aged \u226575 years had significantly shorter EFS compared with patients aged 65 to 69 and 70 to 74 years, with 12-month EFS estimates of 34%, 43%, and 52%, respectively (P\u00a0= .002). The median overall survival was 17.1 months, and there was no significant difference by age groups. The median total health care cost during the 90-day follow-up was $352\u2009572 and was similar across all age groups. CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was low, especially in patients aged \u226575 years, and this age group had a lower rate of EFS, which illustrates the unmet need for more accessible, effective, and tolerable therapy in older patients, especially those aged \u226575 years.<\/jats:p>","DOI":"10.1182\/blood.2023020197","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T21:53:26Z","timestamp":1687298006000},"page":"1047-1055","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":110,"title":["Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Liao","sequence":"additional","affiliation":[{"name":"2ADC Therapeutics, New Providence, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tkacz","sequence":"additional","affiliation":[{"name":"3Inovalon, Bowie, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Franco","sequence":"additional","affiliation":[{"name":"3Inovalon, Bowie, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lewing","sequence":"additional","affiliation":[{"name":"3Inovalon, Bowie, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1103-2107","authenticated-orcid":false,"given":"Karl M.","family":"Kilgore","sequence":"additional","affiliation":[{"name":"3Inovalon, Bowie, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"2ADC Therapeutics, New Providence, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2023092719101863400_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2023092719101863400_bib2","year":"2021"},{"issue":"1","key":"2023092719101863400_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2023092719101863400_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncologist"},{"issue":"31","key":"2023092719101863400_bib5","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023092719101863400_bib6","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023092719101863400_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbmt.2014.01.025","article-title":"High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study","volume":"20","author":"Chihara","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023092719101863400_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10254","key":"2023092719101863400_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"2023092719101863400_bib10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023092719101863400_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023092719101863400_bib12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2023092719101863400_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023092719101863400_bib14","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1097\/HS9.0000000000000185","article-title":"CAR-T cell therapy in diffuse large B cell lymphoma: hype and hope","volume":"3","author":"Hopfinger","year":"2019","journal-title":"Hemasphere"},{"issue":"3","key":"2023092719101863400_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A\u00a0national service for delivering CD19 CAR-T in large B-cell lymphoma - the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2023092719101863400_bib16","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2023092719101863400_bib17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A\u00a0real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"2023092719101863400_bib18","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"issue":"19","key":"2023092719101863400_bib19","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers13194789","article-title":"Real world evidence of CAR T-cell therapies for the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma: a monocentric experience","volume":"13","author":"Casadei","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2023092719101863400_bib20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"issue":"27","key":"2023092719101863400_bib21","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023092719101863400_bib22","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023092719101863400_bib23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"2023092719101863400_bib24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023092719101863400_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma [abstract]","volume":"132","author":"Sano","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023092719101863400_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"2023092719101863400_bib27","unstructured":"Statistics. USBoL\n          . Consumer Price Index: medical care. Medical care in U.S. city average, all urban consumers, not seasonally adjusted. 2021. Accessed 26 February 2022. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm."},{"issue":"suppl 1","key":"2023092719101863400_bib28","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2022-166267","article-title":"Comorbidities associated with early mortality after CD19 CAR-T cell therapy [abstract]","volume":"140","author":"Tang","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023092719101863400_bib29","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2022-165398","article-title":"Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with overall survival (OS) and 1-year mortality in patients (pts) with relapsed or refractory (r\/r) large B cell lymphoma (LBCL) treated with CD19 directed autologous chimeric antigen receptor T (CART) cell therapies [abstract]","volume":"140","author":"Sheng","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023092719101863400_bib30","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2022-169452","article-title":"Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r\/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART) [abstract]","volume":"140","author":"Greenbaum","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023092719101863400_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"2023092719101863400_bib32","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): a three-factor comorbidity model","volume":"27","author":"Gordon","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023092719101863400_bib33","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2023092719101863400_bib34","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the Prospective Elderly Project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10314","key":"2023092719101863400_bib35","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"2023092719101863400_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2023092719101863400_bib37","first-page":"541","article-title":"Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US","volume":"25","author":"Oluwole","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"8","key":"2023092719101863400_bib38","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1007\/s12325-022-02188-0","article-title":"Cost-effectiveness of chimeric antigen receptor T cell therapy in patients with relapsed or refractory large B cell lymphoma: no impact of site of care","volume":"39","author":"Cummings Joyner","year":"2022","journal-title":"Adv Ther"},{"issue":"12","key":"2023092719101863400_bib39","doi-asserted-by":"crossref","first-page":"e2245956","DOI":"10.1001\/jamanetworkopen.2022.45956","article-title":"Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"5","author":"Choe","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2023092719101863400_bib40","first-page":"458","article-title":"Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States","volume":"24","author":"Liu","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"24","key":"2023092719101863400_bib41","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2023092719101863400_bib42","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10306","key":"2023092719101863400_bib43","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023092719101863400_bib44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2023092719101863400_bib45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023092719101863400_bib46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/12\/1047\/2081296\/blood_bld-2023-020197-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/12\/1047\/2081296\/blood_bld-2023-020197-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:10:41Z","timestamp":1695841841000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/12\/1047\/496474\/Real-world-experience-of-CAR-T-cell-therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,9,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020197","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}